Bisphosphonates would also address concerns that an IAP antagonist could induce osteoporosis and secondarily increase bone metastasis by stimulating NF-κB activation and osteoclast formation [46] because they are used to treat osteoporosis and bone metastasis by inhibiting bone resorption [47, 48]. The gene discussed is NFKB1; the disease is osteoporosis.